Comparison · NCT00696072-sae
Dasatinib Plus Letrozole vs Letrozole: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dasatinib Plus Letrozole vs Letrozole: serious adverse events. Trial comparisons, record NCT00696072-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00696072-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.246 | 0.152 | 0.371 | wilson | |
| Risk in group 2 | 0.0317 | 0.00875 | 0.109 | wilson | |
| Risk difference, group 1 minus group 2 | 0.214 | 0.093 | 0.341 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 7.74 | 1.84 | 32.6 | log | |
| Odds ratio, group 1 over group 2 | 9.93 | 2.15 | 46 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Dasatinib Plus Letrozole than on Letrozole | 4.68 | 2.93 | 10.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dasatinib Plus Letrozole | Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years~Dasatinib 100 mg + Letrozole 2.5 mg | 14 | 57 | EG000 |
| Group 2 | Letrozole | Letrozole: Tablets, Oral, 2.5 mg, once daily, up to 2 years | 2 | 63 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- First dose of study drug to last dose plus 30 days
Source ClinicalTrials.gov
Trial
- Title
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
- NCT number
- NCT00696072
- Phases
- PHASE2
- Conditions
- Metastatic Breast Cancer
- Interventions
- Dasatinib, Letrozole
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2016-05-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00696072?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00696072-sae